Laboratoire de Cancérologie et Toxicologie Expérimentale (LCTE)

RESEARCH ACTIVITIES

Véronique’s research activity is mainly focused on deciphering the mechanisms of action of potential anti-cancer compounds from natural origin. Indeed, Nature remains the first source of novel drug leads for anti-cancer purposes with ~60% of the drugs currently available actually inspired by Nature (Cragg and Newman, JNP 2016). The evaluation and understanding of the cellular and molecular effects of such compounds is carried out in Véronique’s team, notably thanks to the use of different imaging tools such as live cell imaging. Véronique is also developing this approach to evaluate the toxicity of compounds for other medical or nutraceutical applications.

TOP 10 RECENT ARTICLES:

1.

Mathieu, V., Chantôme, A., Lefranc, F., Cimmino, A., Miklos, W., Paulitschke, V., Mohr, T., Maddau, L., Kornienko, A., Berger, W., Vandier, C., Evidente, A., Delpire, E., Kiss R. (2015, October). Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. Cell Mol Life Sci. 72(19):3731-46.

2.

Mathieu, V., Van Den Berge, E., Ceusters, J., Konopka, T., Cops, A., Bruyère, C., Pirker, C., Berger, W., Trieu-Van, T., Serteyn, D., Kiss, R., Robiette R. (2013, September). New 5-Aryl-1H-imidazoles display in vitro antitumor activity against apoptosis-resistant cancer models, including melanomas, through mitochondrial targeting. J Med Chem, 56(17):6626-37.

3.

Mathieu, V., Wauthoz, N., Lefranc, F., Niemann, H., Amighi, K., Kiss, R., Proksch, P. (2013, March). Cyclic versus hemi-bastadins. pleiotropic anti-cancer effects: from apoptosis to anti-angiogenic and anti-migratory effects. Molecules, 18(3):3543-61.

4.

Mathieu, V., de Lassalle, E. M., Toelen, J., Mohr, T., Bellahcène, A., Van Goietsenoven, G., Verschuere, T., Bouzin, C., Debyser, Z., De Vleeschouwer, S., Van Gool, S. W., Poirier, F., Castronovo, V., Kiss, R., and Feron, O. (2012, September). Galectin-1 in melanoma biology and related neo-angiogenesis processes. Journal of investigative dermatology, 132(9), 2245-2254.

5.

Mathieu, V., Pirker, C., Schmidt, W. M., Spiegl-Kreinecker, S., Lötsch, D., Heffeter, P., Hegedus, B., Grusch, M., Kiss, R., and Berger, W. (2012, April). Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget, 3(4), 399-413.

6.

Van Goietsenoven, G., Hutton, J., Becker, J.-P., Lallemand, B., Robert, F., Lefranc, F., Pirker, C., Vandenbussche, G., Van Antwerpen, P., Evidente, A., Berger, W., Prévost, M., Pelletier, J., Kiss, R., Kinzy, T. G., Kornienko, A., and Mathieu, V. (2010, November). Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. The FASEB journal, 24(11), 4575-4584.

7.

Mathieu, V., Pirker, C., de Lassalle, E. M., Vernier, M., Mijatovic, T., Deneve, N., Gaussin, J.-F., Dehoux, M., Lefranc, F., Berger, W., and Kiss, R. (2009). The Sodium Pump alpha1 Subunit: a Disease Progression-Related Target for Metastatic Melanoma Treatment. Journal of Cellular and Molecular Medicine, 13(9B), 3960-3972.

8.

Mathieu, V., De Nève, N., Le Mercier, M., Dewelle, J., Gaussin, J.-F., Dehoux, M., Kiss, R., and Lefranc, F. (2008, December). Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia (New York, N.Y.), 10(12), 1383-1392.

9.

Le Mercier, M., Lefranc, F., Mijatovic, T., Debeir, O., Haibe-Kains, B., Bontempi, G., Decaestecker, C., Kiss, R., and Mathieu, V. (2008, June). Evidence of galectin-1 involvement in glioma chemoresistance. Toxicology and applied pharmacology, 229(2), 172-183.

10.

Mathieu, V., Le Mercier, M., De Nève, N., Sauvage, S., Gras, T., Roland, I., Lefranc, F., and Kiss, R. (2007, October). Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. Journal of investigative dermatology, 127(10), 2399-2410.

Véronique Mathieu

Véronique MATHIEU

Faculté de Pharmacie

tel 02 650 5179,

Campus de la Plaine

ULB CP205/01, boulevard du Triomphe, 1050 Bruxelles

Career

Assistant Professor in the Laboratoire de Cancérologie et Toxicologie Expérimentale, Université Libre de Bruxelles (octobre 2011-)

Post-Doctoral Fellow (« Chargé de Recherche ») at the « Fonds National de la Recherche Scientifique »: Université Libre de Bruxelles, Laboratory of Toxicology, Faculty of Pharmacy and FATH, Pharmacy Faculty, Université Catholique de Louvain (2009-2011)

Post-Doctoral Fellow (Yvonne Boël Fundation) : Université Libre de Bruxelles, Laboratory of Toxicology, Faculty of Pharmacy (2007-2009)

Medicine and Laboratory Animal Sciences Certificate: Université Catholique de Louvain (2009), Belgium

PhD in Biomedical Sciences, Pharmaceutical applications section: Université Libre de Bruxelles, Laboratory of Toxicology, Faculty of Pharmacy (2003-2007), Belgium

Physician, Université Libre de Bruxelles (1995-2002), Belgium